Group items tagged

The British Generic Manufacturers Association (BGMA) has elected Diane DiGangi Trench to be its new vice-chair. DiGangi Trench takes up the position replacing Xiromed's Peter Ballard and in 12-months' time will assume the association's chair role from Accord's Peter Kelly. With over 25 years of pharmaceutical industry experience, DiGangi Trench has held a number of senior commercial roles including stints with Takeda and Astra Zeneca. She joined Sandoz in 2018 in the US, where she served as Vice-President, Market Access and Patient Services. In 2021, she became the head of Sandoz' UK business and in her two years in role, she has led the organisation through a post-COVID recovery and growth phase to prepare for the proposed spin out of the company from its parent, Novartis, expected later this year. She said: "It's a great honor to take on the role of Vice Chair of the BGMA. The success of the generics and biosimilar industry is essential to the functioning of the NHS. Generic medicines fill four out of five UK prescriptions and biosimilars enable the NHS to expand access to more patients. I am passionate about increasing the sustainability of our industry so we can continue to play our vital part in the health of the nation." Mark Samuels, BGMA chief executive, said: "We are extremely fortunate to be able to call upon the expertise of Diane who has already added significant value through her role on the BGMA board and leadership of a key strategic committee.

Buy Votrient 200 Mg Pazopanib Hydrochloride Tablets India-Russia , Votrient-200Mg is not a chemotherapy drug but one of many "targeted therapies." Targeted therapy is the result of about 100 years of research dedicated to understanding the differences between cancer cells and normal cells. We are leading suppliers & exporters of "Votrient 200Mg" in China, Russia, Hongkong, Bulgaria, Romania, India, UK, USA. We're largest suppliers of Glaxo Smith Kline medicines & provide you the best price on Votrient. The lowest price sellers, suppliers, distributors & Exporters from Delhi. For more info please contact us. Buy Votrient 200 Mg Pazopanib Hydrochloride Tablets India Votrient 200Mg Suppliers India Pazopanib is used to treat kidney cancer. It may also be used to treat certain other types of cancer (soft tissue sarcoma). Pazopanib belongs to a class of drugs known as Tyrosine Kinase Inhibitors. It works by decreasing the blood supply to the cancer tumor to slow tumor growth. VOTRIENT may shrink or slow the growth of the cancer by interfering with the function of a protein called vascular endothelial growth factor. It is used to treat adults with metastatic renal cell carcinoma, a form of kidney cancer.. Itmay shrink or slow the growth of kidney cancer for a period of time. we are leading suppliers & exporters of Votrient 200Mg Pazopanib Hydrochloride Tablet in China, Russia, Hongkong, Bulgaria, Romania, India, UK, USA and many more And the largest suppliers-exporters of "Glaxo smith Kline" medicines & provide you the best price on Votrient 200Mg Pazopanib Hydrochloride Tablet. The lowest price sellers, suppliers, distributors & Exporters from Delhi For More Info Please Contact us. Brand Name - Votrient Generic - Pazopanib Hydrochloride Strength - 200 Mg Form - Tablets Packing - 1 X 30 Manufactured by - Glaxo smith Kline Warning: Votrient 200Mg medicine out of the reach and sight of children and away from pets, never share your medic

The Competition Appeal Tribunal (CAT) has upheld the Competition and Markets Authority's (CMA) findings against two pharmaceutical manufacturers who consistently overcharged hydrocortisone tablets for over a decade. Auden/Actavis UK's pricing for the critical medicine 'hydrocortisone' from 2008 to 2018 constituted an abuse of their dominant market position, leading to fines nearing £130 million, CMA said in a statement. "These companies increased the price of this crucial medicine by over 10,000 per cent, soaring from 70p to £72 within that period. These are the highest ever CMA penalties upheld by the Tribunal," the CMA said. In July 2021, the CMA imposed fines exceeding £265 million on hydrocortisone manufacturers Auden Mckenzie and Actavis UK, which acquired Auden's business in 2015 and subsequently became Accord-UK. The fines were imposed for abuse of dominance and collusion by both the parent companies and potential competitors. The recent verdict, announced on September 18, comes five weeks after the Tribunal supported the CMA's decision in a separate case regarding the pricing of medicines supplied to the NHS. In that prior case, fines amounted to £84 million.

The British Generic Manufacturers Association (BGMA) has sought a judicial review of the Department of Health and Social Care's (DHSC) decision to negotiate a new Voluntary Scheme for branded medicines with the Association of the British Pharmaceutical Industry (ABPI). Mark Samuels, Chief Executive of BGMA said: "The Government has decided not to involve the trade body representing these medicine suppliers in its negotiations on the voluntary scheme for branded medicine pricing (VPAS). "We are deeply concerned by this decision. It has left us no choice but to take legal action." "While not all generic drugs fall within VPAS, four out of ten products in the current scheme are branded generics or biosimilars. As the representative trade body for both generic and biosimilar UK manufacturers, we must play a full part in the VPAS negotiations for the next period of the scheme from 2024 to 2028." "The VPAS tax has risen five-fold in under two years, an unprecedented tax increase. Yet our sector currently has no input into the negotiations on future schemes or rates; this is untenable as any decisions made on VPAS could significantly define the future of our sector in the UK and its ability to supply the NHS. The association had raised its full participation in the negotiations with the Government last November.

Abirapro 120 Tablets Suppliers in India, Abirapro contains Abiraterone Acetate. Abirapro is manufactured by Glenmark Pharma. This Medicine is available in 250 Mg Tablets Form. We are leading suppliers & exporters of "Abirapro 250Mg" in China, Russia, Hongkong, Bulgaria, Romania, India. And the largest suppliers-exporters of "Glenmarks Onkos" medicines & provide you the best price on Abirapro Abiraterone acetate. The lowest price sellers, suppliers, distributors & Exporters from Delhi-India. Abirapro 250 mg Tablet is an anticancer drug basically used in men along with another drug called prednisone for the treatment of prostate cancer that has spread to other parts of the body. As It is generally used in patients who are not responding to other treatment options. Abirapro 120 Tablets Suppliers in India Abirapro 120 Tablets Suppliers in India, Abirapro 120 Tablets Suppliers in Russia Buy Online Abirapro 120 Tablets Buy Now Description: Brand name - Abirapro Generic name - Abiraterone acetate Strength - 250 Mg Form - Tablets Packing - 1 X 120 Manufactured by - Glenmark (onkos) it's a Glenmarks Oncolgy anti cancer Division Usage : Clinical Packaging Type : Box Expert Advice:Well "Abirapro 250 mg Tablet" treats prostate cancer that has spread to other parts of the body. Usually it can be taken with another medicine called prednisolone to reduce unwanted side effects. Always remember that it must be taken on an empty stomach. Don't eat any food for at least 2 hours before or 1 hour after your dose. How It Works: Take Abirapro 250 mg Tablet as instructed by your doctor. Don't take it in larger amounts as advised/prescribed. Immediately Consult the doctor if you experience any undesirable side effects. Be sure that the treatment course is completed. Don't stop the use of this medicine/tablet without consulting your doctor. Note: Abirapro 250Mg is a prescription Drug and should be used under Proper Medical Guidance and Advice. Do no

Alliance Healthcare UK has won a 'special achievement' award for its work during the Covid-19 pandemic at the Logistics UK Awards 2021. The pharmaceutical wholesaler and it's subsidiary, Alloga UK - a specialist provider of supply chain solutions for healthcare manufacturers - received the 'Special Recognition Award for Outstanding Response to Covid' at an event held in central London on Thursday, December 9, 2021 - beating off stiff competition from a number of high profile challengers. Alliance Healthcare's new managing director Marie Evans said: "I am delighted that our business and team of 6,000 colleagues have been recognised at this level for our contribution to the fight against Covid-19. Our main aim over this unprecedented period is to support the NHS, pharmacy and all UK patients, and this award is true recognition for all of that hard work and dedication." The special award category was open to an individual or organization that demonstrated an outstanding response to the pandemic in 2020 within the logistics sector and included seven other nominees including the likes of National Highways, Hermes UK and Yodel.

The British Generic Manufacturers Association (BGMA) on Monday alerted the Health and Social Care Committee that medicines shortages have increased and are "around double what they were a year ago." BGMA chief executive Mark Samuels told the committee that they have been highlighting the medicine shortage risk to ministers since July 2021 and the association is "very concerned" about the current situation. "We've been monitoring it for several years now, and as you saw in the written evidence, shortages have increased. They're around double what they were a year ago. We have them at 101 shortages in February this year," said Samuels. Dr Rick Greville, director of distribution and supply at the Association of the British Pharmaceutical Industry (ABPI), highlighted that the problem of drug shortages in the UK is a "long-standing issue" and the scarcity of certain medications "continues to be challenging".

Alliance Healthcare, the UK's largest pharmaceutical wholesaler, has pledged to support the global efforts to cut carbon emissions, as set out at the recent UN Climate Change Conference, COP26. The company's pledge is in line with its aim to create "healthier futures and thebusiness", on which it has been working on for years. It aims to become the most sustainable independent full-line pharmaceutical wholesaler in the UK by 2030, ensuring to remain the sustainable partner of choice for its customers and manufacturers.

Dr Nik Kotecha OBE, chairman of Morningside Pharmaceuticals and the Randal Charitable Foundation, has won the Distinguished Alumni Award at Imperial College London's Alumni Awards 2022. The annual awards honour outstanding alumni who have demonstrated sustained excellence in their personal and professional achievements and have made a substantial impact on society. Dr Kotecha, who founded Morningside in 1991, which manufactures and supplies generic and branded medicines to the UK and globally, said: "I'm thrilled to be honoured by the university in this way. "As a child growing up in Leicester my family had very little, but I was fortunate to be given opportunities to gain a good education. After finishing my degree in Newcastle; Professor Steve Ley FRS at Imperial College took a chance in accepting me into his eminent group and this really was the opportunity I needed to forge a career.

Modulator therapies, manufactured by Vertex Pharmaceuticals (VRTX.O), may no longer be available for new cystic fibrosis (CF) patients in the UK. A draft guidance recently published by the National Institute for Health and Care Excellence (NICE) stated that it would not recommend the use of Kaftrio, Symkevi and Orkambi on new CF patients. Kaftrio and Symkevi are currently recommended for the treatment of cystic fibrosis in patients aged 6 years and older, while Orkambi is used for patients aged 1 and older. The NICE draft guidance highlighted medicine costs and the strain on resources and finances faced by the National Health Service (NHS) as reasons for removing these drugs.

Cutting the red tape that blocks pharmacists to alter the HRT prescription could 'quickly fix' the problem of women unable to access their HRT medicines, the Royal Pharmaceutical Society (RPS) told Daily Mail. RPS has suggested that allowing pharmacists to prescribe alternative HRT treatment amid nationwide shortage of HRT medicine could help the women who are struggling to access these medicines. Thorrun Govind, chair of the English Pharmacy Board, told MailOnline 'changes in prescription rules need to be changed urgently.' She added, 'For the pharmacists on the ground, they need the ability to get rid of this bureaucracy. When you think about it - who's best able to offer an alternative - that tends to be the pharmacist.' MailOnline quoted Professor Claire Anderson, president of the Royal Pharmaceutical Society, as said, 'We welcome the Health Secretary meeting with key suppliers and manufacturers to find solutions to the current shortages. But cutting the red tape holding pharmacists back could provide a 'quick fix' that would allow 'women to access their HRT medicines more speedily'.

Well Pharmacy's parent company, Bestway Group, announced on Wednesday (20 March) that it recorded a five per cent growth in revenues to £4.74 billion for the year ending June 2023, alongside a pre-tax profit of £420.9 million. During the year, the company also completed acquisition of Lexon UK Holdings, a leading pharmaceutical wholesaler serving over 3,000 retail pharmacy customers across the UK and Eire. Furthermore, the Group completed the construction of two cement plants in Pakistan, bringing its total cement manufacturing capacity to 15.3 million tonnes per annum. Sir Anwar Pervez OBE, founder and chairman of Bestway Group, expressed optimism about the new business year and said: "The Group has continued on its growth trajectory in 2023 and we are confident that our businesses will continue to gain share within their respective markets during 2024."

Velpanat 400Mg Suppliers Price India, , we are leading suppliers and exporters of velpanat 400mg (Velpatasvir and Sofosbuvir) tablets in China, Russia, Hongkong, India. Modern times medicine provide the best price on Velpanat 400 Mg tablet which you can- not buy from other venders. As a leading suppliers we ensure our customers that we are commited to on-time deliverly of the product that you buy from us. We are leading suppliers & exporters of "Velpanat 400Mg" in China, Russia, Hongkong, Bulgaria, Romania, India, Uk, USA. We're largest suppliers of Natco medicines & provide you the best price on Velpanat. The lowest price sellers, suppliers, distributors & Exporters from Delhi. For more info please contact us. Online Velpanat 400Mg tablet suppliers in India Velpanat 400Mg Suppliers India, Velpanat 400Mg Suppliers Russia, Velpanat tablet is a fixed-dose combination tablet containing sofosbuvir and velpatasvir for oral administration which are direct-acting antiviral agents against the hepatits C virus. Sofosbuvir is a nucleotide analog HCV NS5B polymerase inhibitor and velpatasvir is an NS5A inhibitor. Velpanat-tablet contains 400 mg of sofosbuvir and 100 mg of velpatasvir 100mg each tablets. the each tablet of it include the following inactive ingredients:copovidone, croscarmellose sodium, magnesium stearate, and microcrystalline cellulose. Film coated of velpanat medicine each tablet- sofosbuvir 400 mg and ledipasvir 90 mg with a coating material containing the following inactive ingredients: Titanium Dioxide IP and Brilliant blue FCF, polyethylene glycol, polyvinyl alcohol and titanium dioxide. The effect of sofosbuvir 400 mg (recommended dosage) and 1200 mg (three times the recommended dosage) on QTc interval was evaluted in an active-controlled (moxifloxacin 400 mg) thorough QT trial. Buy Online Suppliers price of Velpanat 400Mg India Details of velpanat tablet- Brand name - Velpanat Tablets Generic of medicine - Velpatasvir and Sofsob

Weight loss drug Wegovy has transformed the obesity market and pharmaceutical companies with existing treatments are hoping the resulting demand will boost demand for their older, less effective but cheaper, drugs. A weekly injection of Wegovy, which was launched in the U.S. in June 2021, leads to an average weight loss of around 15%, alongside changes to diet and exercise. Its impact has captured the attention of patients, investors and even celebrities. But supply issues for Wegovy manufacturer Novo Nordisk means the Danish drugmaker has struggled to meet surging U.S. demand, delaying a launch in most of Europe. Insurers and some national governments have also baulked at its cost, while a minority of patients do not respond to it. Vivus and Currax Pharmaceuticals, U.S.-based developers whose treatments have been on the U.S. market for around a decade, hope to benefit from the attention and supply shortage. But scientists and investors say that lower efficacy plus side effects could continue to hold the treatments back.

The British Generic Manufacturers Association (BGMA) has published a positioning paper which sets out the objectives that need to be delivered through the next Voluntary Pricing and Access Scheme (VPAS) on Thursday (15 June). The paper details how a financially sustainable VPAS can support widened medicines access to patients. VPAS is an agreement between the Department of Health and Social Care (DHSC), NHS England and The Association of the British Pharmaceutical Industry (ABPI). The scheme aims to limit increases in spending on branded medicines to no more than 2% per year via a rebate system which is charged on companies' sales revenues. Two years ago, the rate was 5.1% but for 2023 it has soared to 26.5%. Last year, the association had raised concerns over the rise in the VPAS rate for 2023 to 26.5 per cent. "The rocketing rate is in large part due to the growth in spend in on-patent medicines since 2019. Looking at the four completed years of the current VPAS scheme, data shows that the average annual growth rate for on-patent medicine sales value from 2019-22 was 18% compared to just 2% for off-patent products," said the association.

The Department of Health and Social Care (DHSC) has published the full text of the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG). The 2024 VPAG agreement text sets out the detailed terms of the agreement reached between DHSC, NHS England and the Association of the British Pharmaceutical Industry (ABPI) to support patient access to medicines, the financial sustainability of the NHS and the UK life sciences sector. The new voluntary scheme will come into force on 1 January 2024, following expiry of the 2019 Voluntary Scheme and shall remain in force for a period of five years, until 31 December 2028. Manufacturers or suppliers of branded medicines to the NHS have been given time till 15 January 2024 to decide whether to join the new 2024 Voluntary Scheme, or default to the updated Statutory Scheme.

The British Generic Manufacturers Association (BGMA) has elected Matthew Salzmann, UK Country Manager at Viatris, as its new Vice-Chair with immediate effect. He will replace the current chair of the BGMA, Diane DiGangi-Trench, who is the UK country head for Sandoz. Salzman, who is originally from Australia, has served approximately 1 billion patients worldwide last year as the UK Country Manager at Viatris, a global pharmaceutical company operating in 165 countries. In his role as BGMA Vice-Chair, Salzmann would focus on working in partnership with key stakeholders - the NHS, healthcare professionals, policy makers, clinical societies, patient associations, academia - to ensure access to affordable and sustainable medicines for patients and the NHS.

Hundreds of workers at pharmaceutical giant GlaxoSmithKline are set to strike over a "derisory" pay offer way below the level of British inflation, a union said on Wednesday (April 20). Unite general secretary Sharon Graham accused GSK of "colossal corporate greed" over an effective pay cut in real terms as Britain experiences its highest inflation in 30 years. GSK said it was "disappointed that the Unite union has taken the decision to strike", adding that the British group "remains committed to… a solution". It said in a statement: "We recognise the impact inflation rates are having on people around the country and are strongly committed to supporting the skilled people who work in GSK manufacturing." About 500 Unite members, or around 13 per cent of GSK's UK manufacturing workforce, voted to strike, the drugs group said. GSK said it had offered a four-percent increase in base salary plus one-off awards.

The High Court has dismissed the British Generic Manufacturers Association (BGMA)'s claim on being excluded from ongoing negotiations between the government and industry to agree a new Voluntary Scheme for medicine pricing and access (VPAS). The association had sought a judicial review of the Department of Health and Social Care's (DHSC) decision to negotiate a new Voluntary Scheme for branded medicines with the Association of the British Pharmaceutical Industry (ABPI) in April. Commenting on the result of the case, Richard Torbett, Chief Executive of the ABPI said: "For over 60 years the ABPI has acted as the representative industry body for negotiations on the Voluntary Scheme for branded medicines - a responsibility we take extremely seriously - and one which has been reaffirmed by today's judgment. "While we were disappointed that the BGMA decided to take this action - we recognise their decision was driven by the extreme challenge placed on all parts of the industry from the surge in the branded medicine payment rates. "The solution to these problems must be a completely new and sustainable approach to medicines provision in the UK which rapidly brings industry revenue payments in line with comparator countries to unlock investment and growth."

he Healthcare Distribution Association (HDA) and the Pharmaceutical Services Negotiation Committee (PSNC) have urged the NHS England and the Department of Health and Social Care (DHSC) to issue urgent communications requesting that all those involved in medicines supply do not hoard, stockpile or over-prescribe Strep A antibiotics. In a statement HDA said that the sudden spike in demand for antibiotics used for the treatment of Strep A has meant that there is not enough of these medicines in the supply chain currently to meet this increased demand. As a result, wholesalers are working extremely hard with manufacturers to increase the supply of antibiotics. It added: "As regards pricing, the prices charged to pharmacies by HDA wholesale distributors will directly reflect the increase in prices wholesalers are having to pay for these medicines from manufacturers at the moment, in order to be able to continue supplying these medicines to pharmacies. This will be the case until supply and demand are more in sync."